Pfizer (PFE) stock vs the S&P 500 and pharmaceutical stocks
As of 12 October 2026, Pfizer (PFE) is beating both the S&P 500 and pharmaceutical stocks as a group (PPH) over the past three months.
Where Pfizer stands now
As of 12 October 2026, Pfizer gives a mixed picture against the S&P 500, ahead on some windows and behind on others.
Inside its group, PFE leads: it is ahead of pharmaceutical stocks (PPH) over both the past month and three months. As a group, pharmaceutical stocks are trailing the S&P 500 right now. A strong stock in a weak group: it holds up while its peers struggle.
Pfizer is 5.0% of PPH, so its moves weigh on the fund. It sits in 3 of the sector and theme funds Zensei tracks. The thing to watch is the gap to its group: as long as it stays ahead of both the market and its peers, the trend is intact.
Pfizer competitors and peers
The largest other holdings of VanEck Pharmaceutical ETF (PPH), by weight in the fund, with their plain return over the past month.
Is Pfizer in the S&P 500?
As of 12 October 2026, Pfizer is in the S&P 500. Its sector fund, Healthcare (XLV), holds it at 2.6% weight.
Every stock in one of the 11 S&P 500 sector funds is in the index. See Healthcare Stocks (XLV)
Pfizer ETF: the funds that hold PFE
3 funds that Zensei tracks hold PFE. The main sector is the fund Zensei groups it with. The other funds follow by weight.
PFE stock performance: 1-month, 3-month and 1-year vs the S&P 500
Pfizer and the S&P 500 (SPY) side by side, over each window Zensei tracks.
Prices as of · computed from daily adjusted closes · how we measure
PFE against pharmaceutical stocks, in depth
See the size of the gap between Pfizer and pharmaceutical stocks (PPH) over every window, its momentum and its relative strength, and where it sits among pharmaceutical stocks.
See the full analysisPfizer stock: common questions
Who are Pfizer's competitors?
As of 12 October 2026, the largest other holdings of VanEck Pharmaceutical ETF (PPH) by weight are Eli Lilly (LLY), Merck & Co Inc (MRK), Novo Nordisk (NVO), McKesson Corp (MCK), Bristol-Myers Squibb Co (BMY). These are the stocks Pfizer sits next to among pharmaceutical stocks.
Which ETFs hold Pfizer?
As of 12 October 2026, 3 funds that Zensei tracks hold PFE. Zensei groups it with pharmaceutical stocks in VanEck Pharmaceutical ETF (PPH), where its weight is 5.0%. It is also in Health Care Select Sector SPDR (XLV, 2.6%), SPDR S&P 1500 Momentum Tilt ETF (MMTM, 0.2%).
Is Pfizer in the S&P 500?
As of 12 October 2026, Pfizer is in the S&P 500. Its sector fund, Healthcare (XLV), holds it at 2.6% weight.
What sector is Pfizer in?
As of 12 October 2026, Zensei groups Pfizer with pharmaceutical stocks (PPH, its primary fund). In the S&P 500, it is in the Healthcare sector fund (XLV). It is also in momentum stocks (MMTM).
Is Pfizer stock beating the S&P 500?
As of 12 October 2026, Pfizer (PFE) is up 2.5% over the past month. The S&P 500 is up 2.1% over the same month. Over three months, the stock is up 18.1% and the S&P 500 is up 4.1%.
Is Pfizer doing better than other pharmaceutical stocks?
As of 12 October 2026, Pfizer (PFE) is ahead of pharmaceutical stocks as a group (PPH) over the past three months. Zensei Edge shows the size of the gap, its momentum and its relative strength.
Recent changes
- ·First tracked: beating the market and pharmaceutical stocks
Track Pfizer against pharmaceutical stocks and the market
Zensei Edge maps 100+ sectors and themes against the S&P 500, with each stock inside them measured against its group.